Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Authors:
- 5 May 2022
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 386 (18) , 1766-1768
Abstract
To the Editor: An “organized skepticism” is a fundamental norm of scientific ethos1 and an essential element of the open-science movement.2 Inaccessibility of the informed consent form to the readers of an interventional controlled trial obstructs organized skepticism. This situation becomes more worrisome when the study in question is a safety outcome trial. There is good evidence that what informed consent entails is poorly understood by patients.3 We believe that this understanding is further diminished when the trial that the patients are asked to participate in is a safety outcome trial, because in this setting, the patients are offered treatment . . .Keywords
This publication has 14 references indexed in Scilit:
- Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical ProgramInflammatory Bowel Diseases, 2020
- Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative ColitisClinical Gastroenterology and Hepatology, 2020
- Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programmeAlimentary Pharmacology & Therapeutics, 2019
- Comorbidities in inflammatory bowel disease: a call for actionThe Lancet Gastroenterology & Hepatology, 2019
- Informed consent: time for more transparencyArthritis Research & Therapy, 2010
- Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma CharacteristicsCancer Epidemiology, Biomarkers & Prevention, 2006
- Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritisArthritis & Rheumatism, 2006
- The Risk of Lymphoma Development in Autoimmune DiseasesArchives of internal medicine (1960), 2005
- Inflammatory bowel disease is not associated with an increased risk of lymphomaGastroenterology, 2001
- Open Science and Closed Science: Tradeoffs in a DemocracyScience, Technology, & Human Values, 1985